Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-04
2009-12-22
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S331000
Reexamination Certificate
active
07635683
ABSTRACT:
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
REFERENCES:
patent: 6323180 (2001-11-01), Linas-Brunet et al.
patent: 6995174 (2006-02-01), Wang et al.
patent: 7132504 (2006-11-01), Scola et al.
patent: 7135462 (2006-11-01), Scola et al.
patent: 7176208 (2007-02-01), Nakajima et al.
patent: 2004/0106559 (2004-06-01), Wang et al.
patent: 2004/0266668 (2004-12-01), Nakajima et al.
R.C. Griffith et al., “HCV Anti-viral Agents”, Annual Reports in Medicinal Chemistry, vol. 39, p. 223-237. (2004 Elsevier Inc.).
U.S. Appl. No. 11/489,011, filed Jul. 18, 2006, Nakajima et al.
U.S. Appl. No. 11/768,723, filed Jun. 26, 2007, Niu et al.
U.S. Appl. No. 11/768,712, filed Jun. 26, 2007, Niu et al.
Gai Yonghua
Niu Deqiang
Or Yat Sun
Wang Zhe
Elmore Carolyn S.
Elmore Patent Law Group P.C.
Enanta Pharmaceuticals, Inc.
Harlan Edgar W.
Kosar Andrew D
LandOfFree
Quinoxalinyl tripeptide hepatitis C virus inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoxalinyl tripeptide hepatitis C virus inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoxalinyl tripeptide hepatitis C virus inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4125008